Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Next Previous
Trial Profile

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpelisib (Primary) ; Binimetinib (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Fulvestrant (Primary) ; Ipatasertib (Primary) ; Nilotinib (Primary) ; Olaparib (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Palbociclib (Primary) ; Panitumumab (Primary) ; Selumetinib (Primary) ; Sotorasib (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Endometrial cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Therapeutic Use
  • Acronyms ComboMATCH

Most Recent Events

  • 19 Apr 2024 The procedures of ECHO and MUGA are added to the EAY191-N2 cohort1 (arm 1 and 2) and cohort 2.
  • 28 Jul 2023 Number if treatment arms increased from 14 to 18 by the addition of the following arms: Experimental: EAY191-A2 (Cohort 3, Arm D), Experimental: EAY191-A2 (Cohort 2, Arm C), Experimental: EAY191-A2 (Cohort 2, Arm B) and Experimental: EAY191-A2 (Cohort 2, Arm B). Alpelisib is newly added as a study drug through the new arms.
  • 16 Mar 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top